Individualizing the Management of Hematologic Malignancies: Genomics, Targeted Therapeutic Options, and Treatment Sequencing

REGISTER NOW!
Already Registered?
SIGN IN

WEBCAST DATE

Thursday, June 27, 2019

6:00 PM Eastern    5:00 PM Central    4:00 PM Mountain    3:00 PM Pacific

PROGRAM FEATURES

• Virtual Reality headsets provided to all attendees for viewing this presentation only
• Interactive, case-based learning environment
• Create your own Personalized Poster
• iPads provided to enhance learning experience and enable real-time Q&A

FACULTY

Michael R. Grunwald, MD
Director, Leukemia Section
Associate Professor, Atrium Health
Department of Hematologic Oncology and Blood Disorders Levine Cancer Institute
Charlotte, NC

Ryan Jacobs, MD
Clinical Assistant Professor of Medicine
UNC-Chapel Hill School of Medicine
Chapel Hill, NC
Director of CLL Clinical Trials
Department of Hematology, Lymphoma Division
Levine Cancer Institute/Atrium Healthcare
Charlotte, NC

LEARNING OBJECTIVES

After completing the educational activity, learners should be better able to:

• Assess the treatment implications of common mutations and abnormalities, such as del(17p), del(11q), and mut TP53 for patients with previously untreated and relapsed/refractory (R/R) CLL and AML
• Describe current and novel therapeutic approaches for patients with previously untreated and R/R CLL and AML
• Plan individualized treatment strategies of sequential and combination regimens for patients with previously untreat-ed and R/R CLL and AML by integrating new and/or emerging agents into the current treatment paradigm, with consideration of risks related to adverse events
• Discuss strategies that will improve communication, engagement, education, and decision making with patients who have previously untreated and R/R CLL and AML and their healthcare providers

TARGET AUDIENCE

This activity is designed to meet the needs of US-based hematologists, medical oncologists, oncology nurses, and other healthcare providers involved in the treatment of AML and CLL.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity is planned and produced in accordance with ACCME Essentials.
 

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 2.0 AMA Category 1 Credit(s)^TM.
 
Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AML an CLL.

CNE Credits: 2.0 ANCC Contact Hour(s)

ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of c ontinuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
 
Awarded 2.0 contact hour(s) of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.